Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
Journal
Journal of Clinical Oncology
Journal Volume
35
Journal Issue
12
Pages
1374
Date Issued
2017
Author(s)
Other Subjects
epidermal growth factor receptor; erlotinib; gefitinib; erlotinib; gefitinib; quinazoline derivative; cancer chemotherapy; cancer patient; cancer recurrence; cancer staging; cancer survival; comparative effectiveness; drug efficacy; gene mutation; human; Letter; lung adenocarcinoma; maximum tolerated dose; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); treatment duration; lung adenocarcinoma; lung tumor; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines
Publisher
American Society of Clinical Oncology
Type
letter